Design Therapeutics DSGN
NASDAQ DSGN
$11.10 +0.46 (+4.32%)
At close: Oct 20, 2026 · 4:00 PM EDT

Design Therapeutics (DSGN) EBITDA Margin (2020)

Updated

Design Therapeutics' EBITDA Margin came in at -11687.88% for Q4 2020.

Analysis

Design Therapeutics (DSGN) EBITDA Margin (2020) Analysis & Trends

For FY2020, Design Therapeutics' EBITDA Margin was -3683.63%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn 35.95%
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn 49.01%
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn 6.02%
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn -
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn 33.11%
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn -124.26%
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn 39.16%
10 Design Therapeutics 693.18 Mn -162.85 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 -11,687.88%
API Access

Design Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=DSGN&period=max&api_key=YOUR_API_KEY